Premium
Review of Combination of Peritoneal Dialysis and Hemodialysis as a Modality of Treatment for End‐stage Renal Disease
Author(s) -
Hiroyoshi Fukui,
Sigeko Hara,
Y Hashimoto,
T Horiuchi,
Masaya Ikezoe,
Noritomo Itami,
Mika Kawabe,
Hideki Kawanishi,
Hiroyuki Kimura,
Yasushi Nakamoto,
Masato Nakayama,
Minoru Ôno,
Ota K,
Takeshi Shinoda,
Takao Suga,
Tetsuya Ueda,
Makoto Fujishima,
Teruhiko Maeba,
Akihiro Yamashita,
Yasuyuki Yoshino,
Syunsuke Watanabe
Publication year - 2004
Publication title -
therapeutic apheresis and dialysis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.415
H-Index - 53
eISSN - 1744-9987
pISSN - 1744-9979
DOI - 10.1111/j.1526-0968.2004.00107.x
Subject(s) - medicine , peritoneal dialysis , hemodialysis , continuous ambulatory peritoneal dialysis , medical prescription , intensive care medicine , dialysis , end stage renal disease , ambulatory , urology , surgery , pharmacology
Because the contribution of residual renal function (RRF) to total solute clearance is often significant in continuous ambulatory peritoneal dialysis (CAPD), loss of RRF over time can lead to inadequate dialysis if appropriate prescription management strategies are not pursued. Additionally, declines in ultrafiltration caused by increases in peritoneal permeability may limit continuation of CAPD therapy. Peritoneal dialysis and hemodialysis (PD + HD) combination therapy (complementary dialysis therapy) is an alternative method. This therapy allows the patient to maintain daily activities, as with CAPD, while undergoing once‐a‐week HD supplements for the insufficient removal of solutes and water. This therapy allows for the continuation of PD without shifting to total HD in PD patients who continue to have uremic symptoms even after individualization of the PD prescription. This treatment option is psychologically more acceptable to patients and may be expected to provide such accompanying beneficial effects as peritoneal resting, improvement of QOL and reduction in medical cost.